Antidepressant prescription in acute myocardial infarction is associated with increased mortality 1 year after discharge

Published:January 28, 2019DOI:


      • A number of acute myocardial infarction patients (6%) received antidepressants.
      • Baseline characteristics of these patients differed from those who did not.
      • After adjustment, 1 year mortality remained higher for those with antidepressants.



      To assess the impact of antidepressant (AD) prescription at discharge on 1-year outcome of patients presenting with acute myocardial infarction (AMI) in Switzerland.


      We used data from the AMIS Plus registry including patients admitted between March 2005 and August 2016 with AMI to a Swiss hospital who were followed up by telephone, 12 months after discharge. We compared patients who received AD medication at discharge with those who did not, with regard to baseline characteristics and outcomes in 1-year follow-ups using logistic regression. Outcome endpoints included mortality, re-hospitalisation, cerebrovascular events, re-infarction, percutaneous coronary intervention (PCI), coronary artery bypass graft as well as pacemaker and/or cardioverter-defibrillator implantations. Additionally, work and daily life conditions were compared between the groups.


      Among 8911 AMI patients, 565 (6.3%) received AD at discharge. These patients were predominantly female, older, experienced more often non-ST-segment elevation myocardial infarction, were in higher Killip classes, and had more frequently hypertension, diabetes, dyslipidaemia, obesity and comorbidities. They underwent less frequently PCI, and stayed in hospital longer. The AD-receiving group had higher crude all-cause mortality at 1-year follow-up than the non-receiving group (7.4% vs 3.4%; p < .001) and AD prescription was an independent predictor for mortality (OR 1.67; CI: 1.17 to 2.40).


      AD medication at discharge was associated with poorer prognosis in AMI patients at 1-year follow-up. However, this study has limited data on depression diagnosis and drug classes. Further research is needed to pinpoint the causes and underlying pathomechanisms for the higher mortality observed in this patient group.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Bundesamt für Statistik
        Todesursachenstatistik. Sterblichkeit und deren Hauptursachen in der Schweiz.
        • Reddy K.S.
        Cardiovascular disease in non-Western countries.
        N. Engl. J. Med. 2004; 350: 2438-2440
        • Anand S.S.
        • Islam S.
        • Rosengren A.
        • Franzosi M.G.
        • Steyn K.
        • Yusufali A.H.
        • et al.
        Risk factors for myocardial infarction in women and men: insights from the INTERHEART study.
        Eur. Heart J. 2008; 29: 932-940
        • Lichtman J.H.
        • Froelicher E.S.
        • Blumenthal J.A.
        • Carney R.M.
        • Doering L.V.
        • Frasure-Smith N.
        • et al.
        Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association.
        Circulation. 2014; 129: 1350-1369
        • Wu Q.
        • Kling J.M.
        Depression and the risk of myocardial infarction and coronary death: a meta-analysis of prospective cohort studies.
        Medicine (Baltimore). 2016; 95e2815
        • Stewart J.C.
        • Hawkins M.A.
        • Khambaty T.
        • Perkins A.J.
        • Callahan C.M.
        Depression and anxiety screens as predictors of 8-year incidence of myocardial infarction and stroke in primary care patients.
        Psychosom. Med. 2016; 78: 593-601
        • Bundesamt für Statistik
        in: Taschenstatistik. 2016
        • Kennedy S.H.
        Core symptoms of major depressive disorder: relevance to diagnosis and treatment.
        Dialogues Clin. Neurosci. 2008; 10: 271-277
        • Penninx B.W.
        Depression and cardiovascular disease: epidemiological evidence on their linking mechanisms.
        Neurosci. Biobehav. Rev. 2017; 74: 277-286
        • Mezuk B.
        • Eaton W.W.
        • Albrecht S.
        • Golden S.H.
        Depression and type 2 diabetes over the lifespan: a meta-analysis.
        Diabetes Care. 2008; 31: 2383-2390
        • Luppino F.S.
        • de Wit L.M.
        • Bouvy P.F.
        • Stijnen T.
        • Cuijpers P.
        • Penninx B.W.
        • et al.
        Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies.
        Arch. Gen. Psychiatry. 2010; 67: 220-229
        • Meng L.
        • Chen D.
        • Yang Y.
        • Zheng Y.
        • Hui R.
        Depression increases the risk of hypertension incidence: a meta-analysis of prospective cohort studies.
        J. Hypertens. 2012; 30: 842-851
        • Disante J.L.
        • Bires A.M.
        • Cline T.W.
        • Waterstram-Rich K.
        An analysis of the prevalence of depression post-myocardial infarction.
        Crit. Care Nurs. Q. 2017; 40: 124-136
        • Coupland C.
        • Hill T.
        • Morriss R.
        • Moore M.
        • Arthur A.
        • Hippisley-Cox J.
        Antidepressant use and risk of cardiovascular outcomes in people aged 20 to 64: cohort study using primary care database.
        BMJ. 2016; 352i1350
        • Daskalopoulou M.
        • George J.
        • Walters K.
        • Osborn D.P.
        • Batty G.D.
        • Stogiannis D.
        • et al.
        Depression as a risk factor for the initial presentation of twelve cardiac, cerebrovascular, and peripheral arterial diseases: data linkage study of 1.9 million women and men.
        PLoS One. 2016; 11e0153838
        • Fosbol E.L.
        • Peterson E.D.
        • Weeke P.
        • Wang T.Y.
        • Mathews R.
        • Kober L.
        • et al.
        Spousal depression, anxiety, and suicide after myocardial infarction.
        Eur. Heart J. 2013; 34: 649-656
        • van Melle J.P.
        • de Jonge P.
        • Spijkerman T.A.
        • Tijssen J.G.
        • Ormel J.
        • van Veldhuisen D.J.
        • et al.
        Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis.
        Psychosom. Med. 2004; 66: 814-822
        • Jeger R.
        • Jaguszewski M.
        • Nallamothu B.N.
        • Luscher T.F.
        • Urban P.
        • Pedrazzini G.B.
        • et al.
        Acute multivessel revascularization improves 1-year outcome in ST-elevation myocardial infarction: a nationwide study cohort from the AMIS Plus registry.
        Int. J. Cardiol. 2014; 172: 76-81
        • Charlson M.E.
        • Pompei P.
        • Ales K.L.
        • MacKenzie C.R.
        A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.
        J. Chronic Dis. 1987; 40: 373-383
        • Radovanovic D.
        • Erne P.
        AMIS Plus: Swiss registry of acute coronary syndrome.
        Heart. 2010; 96: 917-921
        • Radovanovic D.
        • Urban P.
        • Simon R.
        • Schmidli M.
        • Maggiorini M.
        • Rickli H.
        • et al.
        Outcome of patients with acute coronary syndrome in hospitals of different sizes. A report from the AMIS Plus Registry.
        Swiss Med. Wkly. 2010; 140: 314-322
        • Hwang C.
        • Levis J.T.
        ECG diagnosis: ST-elevation myocardial infarction.
        Perm. J. 2014; 18: e133
        • Kumar A.
        • Cannon C.P.
        Acute coronary syndromes: diagnosis and management, part I.
        Mayo Clin. Proc. 2009; 84: 917-938
        • Roffman C.E.
        • Buchanan J.
        • Allison G.T.
        Charlson comorbidities index.
        Aust. J. Phys. 2016; 62: 171
        • Mathur R.
        • Perez-Pinar M.
        • Foguet-Boreu Q.
        • Ayis S.
        • Ayerbe L.
        Risk of incident cardiovascular events amongst individuals with anxiety and depression: a prospective cohort study in the east London primary care database.
        J. Affect. Disord. 2016; 206: 41-47
        • Smolderen K.G.
        • Buchanan D.M.
        • Gosch K.
        • Whooley M.
        • Chan P.S.
        • Vaccarino V.
        • et al.
        Depression treatment and 1-year mortality after acute myocardial infarction: insights from the TRIUMPH registry (translational research investigating underlying disparities in acute myocardial infarction patients' health status).
        Circulation. 2017; 135: 1681-1689
        • Taylor C.B.
        • Youngblood M.E.
        • Catellier D.
        • Veith R.C.
        • Carney R.M.
        • Burg M.M.
        • et al.
        Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction.
        Arch. Gen. Psychiatry. 2005; 62: 792-798
        • Frasure-Smith N.
        • Lesperance F.
        • Talajic M.
        Depression and 18-month prognosis after myocardial infarction.
        Circulation. 1995; 91: 999-1005
        • Maqsood S.
        • Jehangiri A.U.R.
        • Khan M.N.
        • Hayat U.
        • Ajmal S.
        • Mushtaq M.
        • et al.
        Depression in myocardial infarction patients at Ayub teaching hospital Abbottabad.
        J. Ayub Med. Coll. Abbottabad. 2017; 29: 641-644
        • Thombs B.D.
        • de Jonge P.
        • Coyne J.C.
        • Whooley M.A.
        • Frasure-Smith N.
        • Mitchell A.J.
        • et al.
        Depression screening and patient outcomes in cardiovascular care: a systematic review.
        JAMA. 2008; 300: 2161-2171
        • Thombs B.D.
        • Roseman M.
        • Coyne J.C.
        • de Jonge P.
        • Delisle V.C.
        • Arthurs E.
        • et al.
        Does evidence support the American Heart Association's recommendation to screen patients for depression in cardiovascular care? An updated systematic review.
        PLoS One. 2013; 8e52654
        • Tonhajzerova I.
        • Visnovcova Z.
        • Mestanikova A.
        • Jurko A.
        • Mestanik M.
        Cardiac vagal control and depressive symptoms in response to negative emotional stress.
        Adv. Exp. Med. Biol. 2016; 934: 23-30
        • Williams M.S.
        • Rogers H.L.
        • Wang N.Y.
        • Ziegelstein R.C.
        Do platelet-derived microparticles play a role in depression, inflammation, and acute coronary syndrome?.
        Psychosomatics. 2014; 55: 252-260
        • Glassman A.H.
        Cardiovascular effects of antidepressant drugs: updated.
        Int. Clin. Psychopharmacol. 1998; 13: S25-S30
        • Cohen H.W.
        • Gibson G.
        • Alderman M.H.
        Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents.
        Am. J. Med. 2000; 108: 2-8
        • Hayes D.
        Recent developments in antidepressant therapy in special populations.
        Am. J. Manag. Care. 2004; 10: S179-S185
        • McFarlane A.
        • Kamath M.V.
        • Fallen E.L.
        • Malcolm V.
        • Cherian F.
        • Norman G.
        Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction.
        Am. Heart J. 2001; 142: 617-623
        • Andrade C.
        • Kumar C.B.
        • Surya S.
        Cardiovascular mechanisms of SSRI drugs and their benefits and risks in ischemic heart disease and heart failure.
        Int. Clin. Psychopharmacol. 2013; 28: 145-155
        • Lopez-Vilchez I.
        • Diaz-Ricart M.
        • Navarro V.
        • Torramade S.
        • Zamorano-Leon J.
        • Lopez-Farre A.
        • et al.
        Endothelial damage in major depression patients is modulated by SSRI treatment, as demonstrated by circulating biomarkers and an in vitro cell model.
        Transl. Psychiatry. 2016; 6: e886
        • van Zyl L.T.
        • Lesperance F.
        • Frasure-Smith N.
        • Malinin A.I.
        • Atar D.
        • Laliberte M.A.
        • et al.
        Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy Trial (CREATE) biomarker sub-study.
        J. Thromb. Thrombolysis. 2009; 27: 48-56
        • Brown T.C.
        • Leversha A.
        Comparison of the cardiovascular toxicity of three tricyclic antidepressant drugs: imipramine, amitriptyline, and doxepin.
        Clin. Toxicol. 1979; 14: 253-256
        • Nee J.
        • Zakari M.
        • Lembo A.J.
        Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome.
        Expert. Opin. Pharmacother. 2015; 16: 2781-2792
        • Savarese M.
        • Carnicelli M.
        • Cardinali V.
        • Mogavero M.P.
        • Federico F.
        Subjective hypnotic efficacy of Trazodone and Mirtazapine in patients with chronic insomnia: a retrospective, comparative study.
        Arch. Ital. Biol. 2015; 153: 231-238
        • Agger J.L.
        • Schroder A.
        • Gormsen L.K.
        • Jensen J.S.
        • Jensen T.S.
        • Fink P.K.
        Imipramine versus placebo for multiple functional somatic syndromes (STreSS-3): a double-blind, randomised study.
        Lancet Psychiatry. 2017; 4: 378-388
        • Almoznino G.
        • Haviv Y.
        • Sharav Y.
        • Benoliel R.
        An update of management of insomnia in patients with chronic orofacial pain.
        Oral Dis. 2017; 23: 1043-1051
        • Zhang M.
        • Li H.
        • Ji Z.
        • Dong D.
        • Yan S.
        Clinical study of duloxetine hydrochloride combined with doxazosin for the treatment of pain disorder in chronic prostatitis/chronic pelvic pain syndrome: an observational study.
        Medicine (Baltimore). 2017; 96e6243